Wall Street brokerages predict that Champions Oncology Inc (NASDAQ:CSBR) will post $0.04 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Champions Oncology’s earnings, with the lowest EPS estimate coming in at $0.03 and the highest estimate coming in at $0.05. The business is scheduled to issue its next earnings report on Thursday, December 6th.
According to Zacks, analysts expect that Champions Oncology will report full-year earnings of $0.17 per share for the current financial year, with EPS estimates ranging from $0.15 to $0.19. For the next year, analysts forecast that the firm will post earnings of $0.25 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last released its earnings results on Thursday, September 13th. The biotechnology company reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.03. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%.
In other news, Director Joel Ackerman sold 22,535 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $17.02, for a total value of $383,545.70. Following the completion of the transaction, the director now owns 1,021,731 shares in the company, valued at approximately $17,389,861.62. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Newman Mendelson sold 8,333 shares of the stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $13.02, for a total transaction of $108,495.66. Following the completion of the transaction, the director now owns 62,500 shares of the company’s stock, valued at approximately $813,750. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,868 shares of company stock valued at $560,791. Corporate insiders own 44.30% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Champions Oncology by 51.4% in the third quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after buying an additional 78,428 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Champions Oncology by 164.3% in the third quarter. Renaissance Technologies LLC now owns 265,846 shares of the biotechnology company’s stock valued at $4,644,000 after buying an additional 165,246 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Champions Oncology in the third quarter valued at $2,162,000. Virtu Financial LLC bought a new position in shares of Champions Oncology in the third quarter valued at $642,000. Finally, BlackRock Inc. grew its stake in shares of Champions Oncology by 656.2% in the third quarter. BlackRock Inc. now owns 123,540 shares of the biotechnology company’s stock valued at $2,158,000 after buying an additional 107,202 shares in the last quarter. 51.37% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:CSBR traded down $0.90 during trading hours on Tuesday, hitting $11.22. 56,300 shares of the company traded hands, compared to its average volume of 111,789. The stock has a market cap of $141.45 million, a P/E ratio of -80.14 and a beta of 0.68. Champions Oncology has a twelve month low of $3.05 and a twelve month high of $17.90. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.73 and a quick ratio of 0.73.
Champions Oncology Company Profile
Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.